Serum Institute to invest Rs 501 crore in Oxford Biomedica
New Delhi: Vaccine maker Serum Institute of India (SII) will invest 50 million pounds ($68 million) in Oxford Biomedica to help fund the development of a plant that manufactures COVID-19 shots, the British company said on Wednesday.Serum - the world's largest vaccine manufacturer by volume - and Oxford Biomedica both produce AstraZeneca's COVID-19 vaccine.Serum Life Sciences Ltd, a unit...
New Delhi: Vaccine maker Serum Institute of India (SII) will invest 50 million pounds ($68 million) in Oxford Biomedica to help fund the development of a plant that manufactures COVID-19 shots, the British company said on Wednesday.
Medical Dialogues team had earlier reported that Novavax, Inc and Serum Institute of India Pvt. Ltd. (SII), had announced a regulatory submission to the World Health Organization (WHO) for Emergency Use Listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
Read also: Serum Institute, Novavax apply to WHO for emergency use listing of Covid-19 vaccine
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd